Considering allogeneic stem cell transplant using digital patient stories and values tools
Official title: Feasibility and Preliminary Efficacy of a Digital Story Intervention to Facilitate Decision-Making in Patients With Myeloid Cancers Considering Allogeneic Hematopoietic Cell Transplantation
Run by University of Rochester · NCT07263074 · Data updated 2026-11-12
This program will test whether digital patient stories plus values-clarification exercises help adults with myeloid cancers who are deciding about allogeneic hematopoietic cell transplantation make choices that fit their goals.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | University of Rochester Academic / other |
| Locations | 1 site (Rochester, New York) |
| Status | Recruiting |
| Started | January 15, 2026 |
| Main results expected | June 30, 2028 |
| Study ends | June 30, 2028 |
| Registry record updated | July 6, 2026 |
| Trial ID | NCT07263074 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 21 with a myeloid malignancy who are being considered for allogeneic hematopoietic cell transplantation, able to consent and speak English, are ideal candidates.
✕Probably not a fit
Patients who are not considering alloHCT, cannot speak English, or have psychiatric or cognitive conditions that preclude informed consent are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a two-arm pilot randomized trial comparing a digital storytelling and values-clarification intervention (CHORDS) to usual care for patients with myeloid malignancies who are considering allogeneic hematopoietic cell transplantation. The CHORDS intervention combines real-life digital videos from patients and caregivers who underwent transplant consultation with an interactive workbook and best-worst scaling exercises to help users reflect on their emotions and priorities. Participants are randomized to receive CHORDS or usual care and outcomes focus on feasibility and preliminary signals of improved decision quality and emotional awareness. The study is conducted at the University of Rochester with adult English-speaking patients and optional caregiver involvement.
Why it matters
Potential benefit: If successful, the intervention could help patients clarify their values, reduce decisional conflict, and make treatment decisions that better match their goals and expectations.
How similar studies have gone: Decision aids and values-clarification tools have shown benefit in other settings, but using digital peer stories specifically to aid alloHCT decision-making is a novel, pilot approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Patients Inclusion criteria: 1. Age \>21 years old 2. Diagnosis of myeloid cancer (e.g. AML, MDS, myelofibrosis, CML, or MDS/MPN) 3. Being considered for alloHCT 4. Able to provide informed consent 5. Able to speak English. The reason for this is because the digital stories have been created in the English language and their multimedia form cannot easily be translated. Exclusion criteria 1) Patients with psychiatric or cognitive conditions which the hematologist believes prohibits informed consent or compliance with study procedures Caregivers Inclusion criteria: 1. Age \>18 years old 2. Selected by the patient when asked if there is a "family member, partner, friend or caregiver with whom you discuss or who can be helpful in health-related matters." 3. Caregiver may be paid/professional or informal caregiver 4. Able to provide informed consent 5. Able to speak English Exclusion Criteria: 1\) None Hematologists Inclusion criteria: 1\) Hematologists of the patients who agree to enroll on the study who are part of WCI. Exclusion criteria 1\) None
Where it's running
-
University of Rochester
Rochester, New York, United States Recruiting
Study contacts
- Study coordinator: Rachel Rodenbach, MD, MS
- Email: rachel_rodenbach@urmc.rochester.edu
- Phone: 585-275-5830
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BG-75202 alone or with other drugs in myeloid malignancies
This study tests BG-75202, a KAT6A/B inhibitor, alone and with other agents to see if it is safe and potentially helpful for adults with myeloid malignancies.
-
RSK1 Inhibitor PMD-026 in myeloid malignancies
A first-in-human test of PMD-026, an oral drug that blocks RSK1, to see if it is safe and can help reduce spleen size and symptoms in people with myelofibrosis and related myeloid conditions.
-
Germline testing for inherited risk of myeloid blood cancers
This research will test whether a germline genetic test (MyeloGen Gene Panel) can find inherited changes linked to myeloid blood cancers in adults who have been diagnosed.
-
Adding decitabine and venetoclax to fludarabine/melphalan reduced‑intensity transplant for myeloid cancers
This study tests whether giving decitabine and venetoclax around a reduced‑intensity allogeneic transplant is safe for adults with high‑risk acute myeloid leukemia or myelodysplastic syndromes.
-
TQB3909 tablets combined with azacitidine for myeloid malignancies
This trial tests whether taking oral TQB3909 together with azacitidine helps adults with myeloid malignancies respond better to treatment and tolerate therapy.
-
Combination treatment for relapsed or refractory acute myeloid leukemia
This study is testing a new combination of three medications to see if it can help people with relapsed or refractory acute myeloid leukemia feel better and improve their treatment results.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.